Biotech trial update: 750 patients have been enrolled ahead of plan in a pivotal study evaluating Symphony™ IL-6 for early assessment of 28-day sepsis mortality risk. The enrollment progress ahead of schedule is a positive operational milestone that may support continued investor confidence ahead of key readouts.
Biotech trial update: 750 patients have been enrolled ahead of plan in a pivotal study evaluating Symphony™ IL-6 for early assessment of 28-day sepsis mortality risk. The enrollment progress ahead of schedule is a positive operational milestone that may support continued investor confidence ahead of key readouts.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
